UEG 2025 4 - 7 October 2025

Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

MASH

Congress poster

GLP-1 RA

Semaglutide

PHASE 3 (RCT)

Are you a healthcare professional?